Annual report pursuant to Section 13 and 15(d)

Shareholders' Equity (Tables)

v3.19.3.a.u2
Shareholders' Equity (Tables)
12 Months Ended
Dec. 31, 2019
Equity [Abstract]  
Schedule of Warrants Outstanding and Exercisable

The Company’s outstanding and exercisable warrants as of December 31, 2019 are presented below:

 

Exercise Price    

Total Warrants

Outstanding

   

Exercisable Warrants 

Outstanding

    Expiration Date  
$ 3.10       48,387       48,387       9/19/2022  
$ 3.10       462,106       462,106       5/10/2024  
$ 3.10       602,414       602,414       7/25/2024  
$ 3.10       1,064,518       1,064,518       11/8/2024  
$ 2.00       900,000       900,000       4/10/2023  
$ 1.00       4,294,500       4,294,500       7/17/2025  
$ 0.75       9,583,334       9,583,334       09/25/2020 *
$ 0.90       9,583,334       9,583,334       3/25/2024  
          26,538,593       26,538,593          

 

* Subject to termination prior to the indicated date following the Company’s release of top-line data related to its Phase 2 double blind, placebo controlled clinical trial of AG013 plus twenty-one (21) trading days.